You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 8,431,806

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,431,806

Title:	Liposomal formulations of anthracycline agents and cytidine analogs
Abstract:	Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Inventor(s):	Mayer; Lawrence (North Vancouver, CA), Johnstone; Sharon (Vancouver, CA), Harasym; Troy (North Vancouver, CA)
Assignee:	Celator Pharmaceuticals, Inc. (Princeton, NJ)
Application Number:	13/237,807
Patent Claims:	1. A composition for parental administration to a subject which composition comprises liposomes having associated therewith daunorubicin and cytarabine, and wherein (a) the daunorubicin and cytarabine are co-encapsulated; (b) the daunorubicin:cytarabine mole ratio is about 1:5; (c) the liposomes have a mean diameter of less than 250 nm; and (d) wherein the liposomes comprise DSPC, DSPG and cholesterol in a mole ratio of about 7:2:1. 2. A method to treat a leukemia in a subject which comprises administering to said subject an effective amount of the composition of claim 1. 3. The method of claim 2, wherein the subject is a human. 4. The method of claim 2, wherein the subject is a non-human mammal or avian. 5. The method of claim 3, wherein the leukemia is ALL or AML. 6. A composition for parental administration to a subject which composition comprises liposomes having associated therewith daunorubicin and cytarabine, and wherein (a) the daunorubicin and cytarabine are co-encapsulated; (b) the daunorubicin:cytarabine mole ratio is about 1:5; (c) the composition comprises no therapeutic agents in addition to the daunorubicin and cytarabine; and (d) wherein the liposomes comprise DSPC, DSPG and cholesterol in a mole ratio of about 7:2:1. 7. A method to treat a leukemia in a subject which comprises administering to said subject an effective amount of the composition of claim 6. 8. The method of claim 7, wherein the subject is a human. 9. The method of claim 7, wherein the subject is a non-human mammal or avian. 10. The method of claim 8, wherein the leukemia is ALL or AML.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.